United Therapeutics (UTHR) EBT Margin (2009 - 2026)

United Therapeutics has disclosed EBT Margin across 18 years of filings, most recently posting 40.73% for Q1 2026.

• EBT Margin for Q1 2026 came in at 40.73%, down 1258.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 50.75% (down 148.0% YoY), and the FY2025 annual result was 53.85%, up 36.0% from the prior year.
• EBT Margin came in at 40.73% for Q1 2026 at United Therapeutics, down from 56.19% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 66.83% in Q1 2022 to a low of 32.26% in Q2 2022.
• The 5-year median for EBT Margin is 53.88% (2024), against an average of 52.12%.
• Peak annual rise in EBT Margin reached 5826 bps in 2022, while the deepest fall reached 1623 bps in 2022.
• United Therapeutics' EBT Margin stood at 36.38% in 2022, then surged by 32 bps to 48.06% in 2023, then gained by 12 bps to 53.88% in 2024, then increased by 4 bps to 56.19% in 2025, then dropped by 28 bps to 40.73% in 2026.
• The last three EBT Margin figures came in at 40.73% (Q1 2026), 56.19% (Q4 2025), and 54.78% (Q3 2025), per Business Quant data.